Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy

Table 1 Patient characteristics n (%)

Characteristics	Patients
Sexe
Male	34 (67.3)
Female	18 (32.7)
Age
< 80	9 (17.0)
≥ 80	43 (83.0)
Tumor location
Colorectal	34 (65.4)
Pancreas	18 (34.6)
Metastasis
≤ 1	26 (50.0)
> 1	26 (50.0)
ECOG performance status
[0-1]	43 (82.7)
[2-3]	9 (17.3)
Comorbidities
No	15 (28.8)
Yes	37 (71.2)
Cardiac comorbidities
No	40 (76.9)
Yes	12 (23.1)
Pulmonary comorbidities
No	47 (90.4)
Yes	5 (9.6)
Hepatic comorbidities
No	52 (100.0)
Yes	0 (0.0)
Albumin level
< 30 g/L	16 (30.8)
≥ 30 g/L	21 (40.4)
Number of usual drugs
< 3	22 (42.3)
≥ 4	30 (57.7)
Charlson comorbidities index
< 10	32 (61.5)
≥ 10	20 (38.5)
Initial autonomy
No	3 (5.8)
Yes	49 (94.2)